Modulation of intracellular restriction factors contributes to methamphetamine- mediated enhancement of acquired immune deficiency syndrome virus infection of macrophages

Current HIV Research

Volumn 10, Issue 5, 2012, Pages 407-414

  Wang, Xu ^a,b   Wang, Yizhong ^b   Ye, Li ^b   Li, Jieliang ^b   Zhou, Yu ^b   Sakarcan, Sinem ^b   Ho, Wenzhe ^a,b  

^a WUHAN UNIVERSITY   (China)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; Interferon; Interferon regulatory factor; Intracellular restriction factors; Macrophages; METH; MicroRNAS; SIV

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; HYDROLASE; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 7; METHAMPHETAMINE; MICRORNA; PROTEIN APOBEC3; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN PIAS 1; PROTEIN PIAS 3; PROTEIN PIAS X; PROTEIN PIAS Y; RETINOIC ACID INDUCIBLE PROTEIN I; SUPPRESSOR OF CYTOKINE SIGNALING 2; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MACROPHAGE; MONOCYTE; MONONUCLEAR PHAGOCYTE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM STIMULANTS; HIV-1; HUMANS; IMMUNITY, INNATE; INTERFERONS; MACACA MULATTA; MACROPHAGES; METHAMPHETAMINE; MICE; SIGNAL TRANSDUCTION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD; VIRUS REPLICATION;

EID: 84866318416     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212802138797     Document Type: Article

References (71)

1. Boddiger D. Metamphetamine use linked to rising HIV transmission. Lancet 2005; 365: 1217-1218.
2. Letendre SL, Cherner M, Ellis RJ, Marquie-Beck J, Gragg B, et al. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS 2005; 19 Suppl 3: S72-S78.
3. Bruneau J, Lamothe F, Soto J, et al. Sex-specific determinants of HIV infection among injection drug users in Montreal. CMAJ 2001; 164: 767-773.
4. Morin SF, Steward WT, Charlebois ED, et al. Predicting HIV transmission risk among HIV-infected men who have sex with men: findings from the healthy living project. J Acquir Immune Defic Syndr 2005; 40: 226-235.
5. Peck JA, Shoptaw S, Rotheram-Fuller E, Reback CJ, Bierman B. HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men. J Addict Dis 2005; 24: 115-132.
6. Plankey MW, Ostrow DG, Stall R, et al. The relationship between methamphetamine and popper use and risk of HIV seroconversion in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2007; 45: 85-92.
7. Shoptaw S, Reback CJ. Associations between methamphetamine use and HIV among men who have sex with men: a model for guiding public policy. J Urban Health 2006; 83: 1151-1157.
8. Shoptaw S, Reback CJ. Methamphetamine use and infectious disease-related behaviors in men who have sex with men: implications for interventions. Addiction 2007; 102 Suppl 1: 130-135.
9. Wohl AR, Johnson DF, Lu S, et al. HIV risk behaviors among African American men in Los Angeles County who self-identify as heterosexual. J Acquir Immune Defic Syndr 2002; 31: 354-360.
10. Patterson TL, Semple SJ, Staines H, et al. Prevalence and correlates of HIV infection among female sex workers in 2 Mexico-US border cities. J Infect Dis 2008; 197: 728-732.
11. Moore RD, Keruly JC, Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr 2004; 35: 46-51.
12. Ellis RJ, Childers ME, Cherner M, et al. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis 2003; 188: 1820-1826.
13. Gavrilin MA, Mathes LE, Podell M. Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes. J Neurovirol 2002; 8: 240-249.
14. Marcondes MC, Flynn C, Watry DD, Zandonatti M, Fox HS. Methamphetamine increases brain viral load and activates natural killer cells in simian immunodeficiency virus-infected monkeys. Am J Pathol 2010; 177: 355-361.
15. Toussi SS, Joseph A, Zheng JH, et al. Short communication: Methamphetamine treatment increases in vitro and in vivo HIV replication. AIDS Res Hum Retroviruses 2009; 25: 1117-1121.
16. Maragos WF, Young KL, Turchan JT, et al. Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J Neurochem 2002; 83: 955-963.
17. Nair MP, Saiyed ZM, Nair N, et al. Methamphetamine enhances HIV-1 infectivity in monocyte derived dendritic cells. J Neuroimmune Pharmacol 2009; 4: 129-139.
18. Liang H, Wang X, Chen H, et al. Methamphetamine enhances HIV infection of macrophages. Am J Pathol 2008; 172: 1617-1624.
19. Yu Q, Larson DF, Watson RR. Heart disease, methamphetamine and AIDS. Life Sci 2003; 73: 129-140.
20. Iwasa M, Maeno Y, Inoue H, Koyama H, Matoba R. Induction of apoptotic cell death in rat thymus and spleen after a bolus injection of methamphetamine. Int J Legal Med 1996; 109: 23-28.
21. House RV, Thomas PT, Bhargava HN. Comparison of immune functional parameters following in vitro exposure to natural and synthetic amphetamines. Immunopharmacol Immunotoxicol 1994; 16: 1-21.
22. In SW, Son EW, Rhee DK, Pyo S. Methamphetamine administration produces immunomodulation in mice. J Toxicol Environ Health A 2005; 68: 2133-2145.
23. In SW, Son EW, Rhee DK, Pyo S. Modulation of murine macrophage function by methamphetamine. J Toxicol Environ Health A 2004; 67: 1923-1937.
24. Everall I, Salaria S, Roberts E, et al. Methamphetamine stimulates interferon inducible genes in HIV infected brain. J Neuroimmunol 2005; 170: 158-171.
25. Hassan NF, Campbell DE, Douglas SD. Purification of human monocytes on gelatin-coated surfaces. J Immunol Methods 1986; 95: 273-276.
26. Lee YW, Hennig B, Yao J, Toborek M. Methamphetamine induces AP-1 and NF-kappaB binding and transactivation in human brain endothelial cells. J Neurosci Res 2001; 66: 583-591.
27. Reynolds JL, Mahajan SD, Sykes DE, Schwartz SA, Nair MP. Proteomic analyses of methamphetamine (METH)-induced differential protein expression by immature dendritic cells (IDC). Biochim Biophys Acta 2007; 1774: 433-442.
28. Kalasinsky KS, Bosy TZ, Schmunk GA, et al. Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users. Forensic Sci Int 2001; 116: 163-169.
29. Klette KL, Kettle AR, Jamerson MH. Prevalence of use study for amphetamine (AMP), methamphetamine (MAMP), 3,4-methylenedioxy-amphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), and 3,4-methylenedioxyethylamphetamine (MDEA) in military entrance processing stations (MEPS) specimens. J Anal Toxicol 2006; 30: 319-322.
30. Schepers RJ, Oyler JM, Joseph RE, et al. Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem 2003; 49: 121-132.
31. Takayasu T, Ohshima T, Nishigami J, Kondo T, Nagano T. Screening and determination of methamphetamine and amphetamine in the blood, urine and stomach contents in emergency medical care and autopsy cases. J Clin Forensic Med 1995; 2: 25-33.
32. Willey RL, Smith DH, Lasky LA, et al. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol 1988; 62: 139-147.
33. Ho WZ, Lioy J, Song L, et al. Infection of cord blood monocytederived macrophages with human immunodeficiency virus type 1. J Virol 1992; 66: 573-579.
34. Wang X, Ye L, Hou W, et al. Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection. Blood 2009; 113: 671-674.
35. Wang X, Ye L, Zhou Y, et al. Inhibition of anti-HIV microRNA expression: a mechanism for opioid-mediated enhancement of HIV infection of monocytes. Am J Pathol 2011; 178: 41-47.
36. Li Y, Zhang T, Douglas SD, et al. Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol 2003; 163: 1167-1175.
37. Zhang T, Lin RT, Li Y, et al. Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. Hepatology 2005; 42: 819-827.
38. Sung TL, Rice AP. miR-198 inhibits HIV-1 gene expression and replication in monocytes and its mechanism of action appears to involve repression of cyclin T1. PLoS Pathog 2009; 5: e1000263.
39. Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300: 1145-1148.
40. Mamane Y, Heylbroeck C, Genin P, et al. (1999) Interferon regulatory factors: the next generation. Gene 237: 1-14.
41. Nguyen H, Hiscott J, Pitha PM. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev 1999; 8: 293-312.
42. Holmes RK, Malim MH, Bishop KN. APOBEC-mediated viral restriction: not simply editing? Trends Biochem Sci 2007; 32: 118-128.
43. Yu Q, Chen D, Konig R, et al. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem 2004; 279: 53379-53386.
44. Norkina O, Dolganiuc A, Catalano D, et al. Acute alcohol intake induces SOCS1 and SOCS3 and inhibits cytokine-induced STAT1 and STAT3 signaling in human monocytes. Alcohol Clin Exp Res 2008; 32: 1565-1573.
45. Theodore S, Cass WA, Nath A, et al. Inhibition of tumor necrosis factor-alpha signaling prevents human immunodeficiency virus-1 protein Tat and methamphetamine interaction. Neurobiol Dis 2006; 23: 663-668.
46. Tata DA, Yamamoto BK. Interactions between methamphetamine and environmental stress: role of oxidative stress, glutamate and mitochondrial dysfunction. Addiction 2007; 102 Suppl 1: 49-60.
47. Hariharan M, Scaria V, Pillai B, Brahmachari SK. Targets for human encoded microRNAs in HIV genes. Biochem Biophys Res Commun 2005; 337: 1214-1218.
48. Huang J, Wang F, Argyris E, et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 2007; 13: 1241-1247.
49. Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006; 6: 644-658.
50. Barnes BJ, Moore PA, Pitha PM. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem 2001; 276: 23382-23390.
51. Marie I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J 1998; 17: 6660-6669.
52. Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006; 25: 349-360.
53. Honda K, Yanai H, Negishi H, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434: 772-777.
54. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev 2009; 227: 75-86.
55. Solis M, Nakhaei P, Jalalirad M, et al. RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I. J Virol 2011; 85: 1224-1236.
56. Chiu YL, Soros VB, Kreisberg JF, et al. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 2005; 435: 108-114.
57. Wang FX, Huang J, Zhang H, Ma X. APOBEC3G upregulation by alpha interferon restricts human immunodeficiency virus type 1 infection in human peripheral plasmacytoid dendritic cells. J Gen Virol 2008; 89: 722-730.
58. Dang Y, Siew LM, Wang X, et al. Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J Biol Chem 2008; 283: 11606-11614.
59. Mbisa JL, Bu W, Pathak VK. APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. J Virol 2010; 84: 5250-5259.
60. Mangeat B, Turelli P, Caron G, et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424: 99-103.
61. Mariani R, Chen D, Schrofelbauer B, et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003; 114: 21-31.
62. Zhang H, Yang B, Pomerantz RJ, et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003; 424: 94-98.
63. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. Embo J 2004; 23: 2451-2458.
64. Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 1992; 70: 313-322.
65. Platanias LC. Mechanisms of type-I- and type-II-interferonmediated signalling. Nat Rev Immunol 2005; 5: 375-386.
66. Theodore S, Cass WA, Maragos WF. Involvement of cytokines in human immunodeficiency virus-1 protein Tat and methamphetamine interactions in the striatum. Exp Neurol 2006; 199: 490-498.
67. Pauli EK, Schmolke M, Wolff T, et al. Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression. PLoS Pathog 2008; 4: e1000196.
68. Theodore S, Cass WA, Maragos WF. Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum. Neuroscience 2006; 137: 925-935.
69. Chung CD, Liao J, Liu B, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997; 278: 1803-1805.
70. Potula R, Hawkins BJ, Cenna JM, et al. Methamphetamine causes mitrochondrial oxidative damage in human T lymphocytes leading to functional impairment. J Immunol 2010; 185: 2867-2876.
71. Theodore S, Stolberg S, Cass WA, Maragos WF. Human immunodeficiency virus-1 protein tat and methamphetamine interactions. Ann N Y Acad Sci 2006; 1074: 178-190.